
AKCA
Healthcare · Biotechnology · $1.85B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 4, 2020 | Time not confirmed | -0.35 | -0.49 | -40.0% |
| May 5, 2020 | Time not confirmed | -0.46 | -0.42 | +8.7% |
| Feb 25, 2020 | Time not confirmed | 1.11 | 0.86 | -22.5% |
| Nov 5, 2019 | Time not confirmed | -0.47 | -0.34 | +27.7% |
| Aug 7, 2019 | Time not confirmed | -0.43 | -0.40 | +7.0% |
| May 8, 2019 | Time not confirmed | 0.98 | 0.29 | -70.4% |
| Feb 26, 2019 | Time not confirmed | -0.73 | -0.79 | -8.2% |
| Nov 5, 2018 | Time not confirmed | -0.80 | -0.73 | +8.8% |
| Aug 6, 2018 | Time not confirmed | -1.24 | -0.75 | +39.5% |
| May 3, 2018 | Time not confirmed | -0.36 | -0.44 | -22.2% |
| Feb 26, 2018 | Time not confirmed | -0.21 | -0.27 | -28.6% |
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial…